Nothing Special   »   [go: up one dir, main page]

Huebinger et al., 2012 - Google Patents

Comparison of protein concentrations in serum versus plasma from Alzheimer's patients

Huebinger et al., 2012

View PDF
Document ID
13378167806988852050
Author
Huebinger R
Xiao G
Wilhelmsen K
Diaz-Arrastia R
Zhang F
O'Bryant S
Barber R
Publication year
Publication venue
Advances in Alzheimer's Disease

External Links

Snippet

Background: There is great interest in developing blood-based biomarkers for Alzheimer's disease (AD); however, there is no consensus as to what blood fraction is most appropriate for analyzing particular markers. The current study provides empirical evidence regarding …
Continue reading at eprints.go2submission.com (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/558—Immunoassay; Biospecific binding assay using diffusion or migration of antigen or antibody
    • G01N33/561—Immunoelectrophoresis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
    • G06F19/28—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for programming tools or database systems, e.g. ontologies, heterogeneous data integration, data warehousing or computing architectures

Similar Documents

Publication Publication Date Title
Bettcher et al. Increases in a pro-inflammatory chemokine, MCP-1, are related to decreases in memory over time
Fillman et al. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia
Boerrigter et al. Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder
Schutzer et al. Distinct cerebrospinal fluid proteomes differentiate post-treatment lyme disease from chronic fatigue syndrome
O’Bryant et al. A blood-based algorithm for the detection of Alzheimer’s disease
van der Ende et al. Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomics
Cvijanovich et al. Validating the genomic signature of pediatric septic shock
Egberts et al. Increased neutrophil–lymphocyte ratio in delirium: a pilot study
Shen et al. Reduced lymphocyte count as an early marker for predicting infected pancreatic necrosis
Barbour et al. Molecular‐based diagnosis of multiple sclerosis and its progressive stage
Toft et al. PTSD patients show increasing cytokine levels during treatment despite reduced psychological distress
Castro-Marrero et al. Circulating extracellular vesicles as potential biomarkers in chronic fatigue syndrome/myalgic encephalomyelitis: an exploratory pilot study
Ng et al. Risk factors, including different biologics, associated with depression and anxiety in patients with rheumatoid arthritis: a cross-sectional observational study
Srinivasan et al. Literature–Based Discovery of Salivary Biomarkers for Type 2 Diabetes Mellitus
Mosca et al. Chemotactic and phagocytic activity of blood neutrophils in allergic asthma
Preziosa et al. Current state-of-art of the application of serum neurofilaments in multiple sclerosis diagnosis and monitoring
Lauffer et al. Predicting persistence of atopic dermatitis in children using clinical attributes and serum proteins
Hasan et al. Quantitative proteome analysis of brain subregions and spinal cord from experimental autoimmune encephalomyelitis mice by TMT‐based mass spectrometry
Muñoz-Delgado et al. Peripheral inflammatory immune response differs among sporadic and familial Parkinson’s disease
Rentzos et al. RANTES levels are elevated in serum and cerebrospinal fluid in patients with amyotrophic lateral sclerosis
Torres et al. Increased frequency of cluster of differentiation 14 (CD14+) monocytes expressing interleukin 1 beta (IL‐1β) in Alzheimer's disease patients and intermediate levels in late‐onset depression patients
McGill et al. Monocyte CD14 and HLA-DR expression increases with disease duration and severity in amyotrophic lateral sclerosis
Brasanac et al. Immune signature of multiple sclerosis-associated depression
O'bryant et al. Molecular neuropsychology: creation of test-specific blood biomarker algorithms
Sørensen et al. Neuroimmunological investigations of cerebrospinal fluid in patients with recent onset depression–a study protocol